CMMB News and Press, Chemomab Therapeutics Ltd. From 11/08/21

Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience PR Newswire TEL AVIV, Israel , Nov. 8, 2021 ...

Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis Live Event featuring Dr. Dinesh Khanna to be Held Wednesday, November 3rd from 10:00 am - 11:00 am ET PR Newswire TEL AVIV, Israel , Oct. 26, 2021 /PRNewswire/ -- Chemomab The...

Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis -Collaboration will study how CCL24, a soluble protein involved in profibrotic and proinflammatory processes, contribu...

Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations PR Newswire TEL AVIV, Israel , Sept. 2, 2021 /PRNewswire/ -...

Chemomab to Participate in Upcoming September Investor Conferences PR Newswire TEL AVIV, Israel , Sept. 1, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovativ...

Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update - CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data expected in 2022 - - Cash and equivalents of $67 million as of June 30, 2021, expecte...

TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a le...

Gainers: Novan (NOVN) +81%, Aptinyx (APTX) +25%, Vaxart (VXRT) +39%, Progenity (PROG) +28%, Chemomab Therapeutics (CMMB) +9%.Losers: Orphazyme (ORPH) -41%, Curis (CRIS) -32%, Aptose Biosciences (APTO) -30%, Galecto (GLTO) -22%,&...

Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re approaching the end of trading for the week but we’ve got one more day of market coverage to bring you. Of course, we’re starting that off with a look at the biggest pre-m...